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Abstract
Amyloid beta-protein (Ah) is thought to be one of the primary factors causing neurodegeneration in Alzheimer’s disease (AD). This
protein is an amphipathic molecule that perturbs membranes, binds lipids and alters cell function. Several studies have reported that Ah alters
membrane fluidity but the direction of this effect has not been consistently observed and explanations for this lack of consistency are
proposed. Cholesterol is a key component of membranes and cholesterol interacts with Ah in a reciprocal manner. Ah impacts on cholesterol
homeostasis and modification of cholesterol levels alters Ah expression. In addition, certain cholesterol lowering drugs (statins) appear to
reduce the risk of AD in human subjects. However, the role of changes in the total amount of brain cholesterol in AD and the mechanisms of
action of statins in lowering the risk of AD are unclear. Here we discuss data on membranes, cholesterol, Ah and AD, and propose that
modification of the transbilayer distribution of cholesterol in contrast to a change in the total amount of cholesterol provides a cooperative
environment for Ah synthesis and accumulation in membranes leading to cell dysfunction including disruption in cholesterol homeostasis.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neuritic plaques and neurofibrillary tangles in brain are
characteristic neuropathological features of Alzheimer’s
disease (AD). Amyloid beta-protein (Ah) is a primary
component of neuritic plaques. Ah is 39–43 amino acid
residues long and that is derived in part from the trans-
membrane region of the amyloid precursor protein (APP)
[1,2]. Observations that Ahwas neurotoxic in cells provided
the first evidence that Ah might be directly involved in
neurodegeneration in individuals with AD [3,4]. Concom-
itantly, it was proposed that the initial pathophysiology
induced by Ah involved alterations in membrane structure
and function [5,6]. Subsequently, there have been an exten-
sive number of studies on effects of Ah on membranes and
cell function (reviewed in Refs. [1,7,8]). There is certainly a
physico-chemical interaction between Ah and membranes,
including but not limited to changes in fluidity, binding to
membranes and lipids including cholesterol. The majority of
studies examining the effects of Ah on membranes have
looked at changes in fluidity but there is no agreement on
effects of Ah on membrane fluidity, and an explanation for
this lack of consistency will be discussed in this review.
Cholesterol is an important component of membranes
and there has been a mounting body of data on Ah and
cholesterol and linking disturbances in cholesterol homeo-
stasis with AD. Sparks et al. [9] were one of the first groups
to suggest a possible link between cholesterol and AD. They
found that patients with critical coronary artery disease also
showed deposition of Ah similar to that seen in AD patients.
Subsequent work of that group showed that high-cholesterol
diets in rabbits induced accumulation of Ah in brain [10].
Linkage of cholesterol and AD was also suggested by the
presence of the apolipoprotein E4 allele and occurrence of
AD [11]. ApoE is an apolipoprotein that transports choles-
terol and individuals with the apoE4 allele are at a greater
risk of developing AD compared to individuals with the
apoE2 or -3 alleles. Further strengthening the association
between cholesterol and AD is recent epidemiological data
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showing that the prevalence of AD is diminished in patients
taking statins [12,13]. Results from experimental studies in
vivo and in vitro provide additional and important support
for a role of cholesterol in AD.
In spite of the large body of data on cholesterol and AD,
there are several major issues that remain unaddressed
regarding the role of cholesterol in AD and these issues will
be examined in this paper. For example, there is little if any
consensus that total or bulk brain cholesterol is altered in AD
patients. Changes in cholesterol domains may be important in
AD in contrast to changes in bulk cholesterol. The mecha-
nisms of action of statins in brain are not well understood and
not all statins are equally effective. There are data showing
that cholesterol may actually inhibit action of Ah. The
purpose of this review is to discuss: (1) data on actions of
Ah in membranes; (2) the role that cholesterol plays in Ah
dynamics and AD; and (3) cholesterol domains and Ah. This
review focuses on membranes and cholesterol but it is
important to point out that other lipids (gangliosides, phos-
pholipids, fatty acids) besides cholesterol interact with Ah
and those lipids also may be essential in the pathogenesis of
AD [14–21].
2. AB is associated with membranes
Localization of Ah1–42 on the cell surface plasma mem-
brane of brain from patients with AD was revealed using
electronmicroscopy [22]. The authors concluded that Ah1–42
deposition on the cell surface plasmamembrane was an initial
event in formation of diffuse plaques that gradually develop
into fibrillar amyloid. Similar findings were recently reported
in aged dogs, which are an accepted model of AD, since dogs
exhibit age-dependent cognitive decline that is correlated
with the accumulation of Ah [23]. Neuronal labeling indi-
cated that Ah1–42 was associated with the neuronal plasma
membrane and it was suggested that the peptide may be
produced at the dendritic plasma membrane. Two pools of
insoluble Ah were identified in human prefrontal cortices
[24]. One pool was located in a cholesterol-enriched low-
density membrane domain while the second pool comprised
extracellular Ah deposits. In the same study, it was shown
that in PDAPP mice that develop plaques and accumulate
Ah, low-density membrane domains showed accumulation
of Ah1–42. Other studies have also reported that APP and Ah
were associated with cholesterol-rich low-density membrane
domains [24–27].
Studies in vitro, using model membranes and biological
membranes, have also shown that Ah associated with mem-
branes. Electrostatic binding of Ah to phospholipid polar
head groups has been proposed to be a mechanism that may
contribute to Ah neurotoxicity [18,28]. Circular dichroism
spectroscopy showed that Ah1–40 interacted with negatively
charged unilamellar vesicles but no effect was detected in
vesicles containing deuterated phosphatidylcholine mixed
with phosphatidylglycerol using deuterium NMR and that
Ah1–40 did not penetrate into membranes [28]. Ah1–40 had a
more pronounced effect on disrupting and aggregating neg-
Table 1
Ah perturbation of membranes
Sample Ah protein Technique Fluidity Reference
SUV 1–40 Polarization of DPH Decrease [6]
Mouse brain membranes 25–35 Anisotropy of DPH Decrease [35]
Mouse brain homogenate 25–35 Anisotropy of DPH Decrease [36]
Human frontal cortex 25–35; 1–28; 1–40;
1–42; 1–43
Anisotropy of DPH Decrease [37]
Human hippocampal tissue, control 25–35; 1–42 Anisotropy of DPH Decrease [38]
Human hippocampal tissue, AD
Mouse SPM, 3 months of age 25–35; 1–40; 1–42 Anisotropy of DPH Decrease [39]
Mouse SPM, 22 months of age 1–42 Anisotropy of DPH Decrease
Liposomes 1–39; 1–40 Anisotropy of DPH Decrease [40]
Mouse SPM, 3 months of age 25–35; 1–40; 1–42 Pyrene eximer/monomer ratio
(bulk fluidity)
No effect
Mouse SPM, 22 months of age Increase
Rat SPM 25–35; 1–40 Pyrene eximer/monomer ratio
(bulk fluidity)
Increase [30,43]
Pyrene eximer/monomer ratio
(annular fluidity)
Increase
Rat SPM from cortex and hippocampus 1–40 Pyrene eximer/monomer
(bulk fluidity)
Increase [44]
Pyrene eximer/monomer ratio
(annular fluidity)
Increase
Rat SPM from cerebellum No effect
Human brain PM 1–40; 1–42 Anisotropy of DPH Decrease [41]
Human brain Golgi Increase
Human brain endosomal and lysosomal membranes Decrease
Brain lipid extract 1–40 Anisotropy of DPH Decrease [42]
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atively charged lipid vesicles than zwitterionic vesicles [18].
Conversely, studies of Ah peptides in bothmodel membranes
and biological membranes indicated that soluble or fresh Ah
partitioned into the hydrophobic core of membranes [29,30].
Liposomes consisting of 1-palmitoyl-2-oleoylphosphatidyl-
choline revealed that the peptide fragment Ah25–35 localized
in the membrane hydrocarbon core [29]. Moreover, soluble
Ah1–40 and aggregated Ah1–40 were found to differ in their
location in rat synaptic plasma membranes (SPM) [30].
Soluble Ah1–40 intercalated into the hydrophobic region of
SPM. Aggregated Ah1–40 was positioned at the polar head
group region of the membrane. Differences in results of the
aforementioned studies may have occurred as a consequence
of variations in peptide structure and dissimilarities in struc-
ture of liposomes versus biological membranes. Results of
studies using the peptide fragment 25–35 have to be viewed
cautiously in view of the fact that this fragment is not present
in vivo. Nevertheless, in can be seen in Table 1 that Ah does
have a physico-chemical interaction with membranes.
It has been previously proposed that Ahmay interact with
lipids both by hydrophobic interactions and electrostatic
interactions at the membrane surface particularly with neg-
atively charged phospholipids [18]. The cytofacial leaflet of
biological membranes is negatively charged as a result of
enrichment of phosphatidylinositol and phosphatidylserine
as compared to the zwitterionic exofacial leaflet. Certain
cationic drugs have been shown to perturb the negatively
charged cytofacial leaflet and anionic drugs perturbed the
zwitterionic exofacial leaflet [31,32]. Electrostatic interaction
of Ahwith phospholipid polar head groups may be greater in
the cytofacial leaflet than the exofacial leaflet and this
prediction is consistent with the affinity of Ah for negatively
charged lipids [18,28].
3. AB and membrane fluidity
Ah disrupts membrane fluidity. Studies have examined
the effects of Ah peptides on membrane fluidity in model
membranes and biological membranes of mice, rats and
humans (Table 1). We use the term fluidity in the broadest
sense to describe an average lateral motion in the membrane
lipid environment without making a distinction between
dynamic and static states of fluorescent probe motion. This
issue is discussed later in this section. It is well recognized
that changes in the physico-chemical state of the membrane
can markedly alter activity of various membrane proteins
[32,33]. Effects of Ah on membrane fluidity have been
proposed as contributing to disruption in different cell func-
tions (e.g., calcium signaling; activity of various enzymes,
lipid transport) [5,34,35].
Ah1–40 was reported to increase polarization of diphenyl-
hexatrine (DPH) in small unilamellar vesicles (SUV) con-
sisting of phosphatidylethanolamine (PE), phos-
phatidylcholine (PC) and cardiolipin [6]. An increase in
polarization of DPH is indicative of a more ordered mem-
brane state. In one of the first studies on Ah and fluidity using
biological tissue, the peptide fragment Ah25–35 increased
anisotropy (i.e., reduced fluidity) of DPH in mouse and rat
brain membranes [35,36]. Several subsequent studies includ-
ing brain tissue from humans with and without AD have
shown that different Ah peptides reduce membrane fluidity
[37–42]. Ah would appear to have a rigidifying effect on
membranes. However, it has been reported that Ah disorders
or increases fluidity of membranes [30,40,41,43,44]. Ah1–40
increased both annular fluidity and bulk fluidity in SPMusing
energy transfer from protein tryptophan residues and excita-
tion of pyrene (annular fluidity) and pyrene excitation alone
(bulk fluidity) [30,40,43,44]. Anisotropy of DPH was
reduced in human brain Golgi membranes in the presence
of Ah1–40,42 but just the opposite effect was noted in endo-
somal, lysosomal and mitochondrial membranes of the same
human brain samples [41]. FTIR-PATR spectroscopy dem-
onstrated that Ah1–40 slightly disordered SUV containing
gangliosides [17].
There is no agreement on effects of Ah proteins on
membrane fluidity. Certainly, differences in effects of Ah
on fluidity could result from the usual suspects such as tissue
source and preparation, whether Ah is soluble or aggregated,
and age of the organism. We propose, however, that the
differences in effects of Ah on fluidity are largely the result of
differences in the location of the fluorescence probes in the
membrane environment and the lifetime of the fluorescence
probes. The majority of studies examining Ah and fluidity
have used steady-state fluorescence of DPH and pyrene
fluorescence. It can be seen in Table 1 that, generally, studies
reporting a reduction in fluidity induced by Ah have meas-
ured polarization or anisotropy of DPH. In contrast, studies
finding that Ah increases membrane fluidity have measured
energy transfer and excitation of pyrene. Structurally, DPH
and pyrene differ and this difference can influence their
behavior in membranes [45,46]. DPH is a rodlike structure
whose axis is parallel to the acyl groups of membranes and
pyrene is spherical in structure and is positioned at the
terminal end of the acyl groups. Lifetime of a fluorescent
probe establishes the duration of time for which the probe
interacts in its environment such as membranes [47]. The
lifetimes of DPH and pyrene differ: average lifetimes approx-
imately 10 vs. 400 ns, respectively [47]. The longer lifetime
of pyrene may increase interaction with different areas of the
membrane. We conclude that the most parsimonious explan-
ation for the reported differences in Ah effects using fluo-
rescence of DPH and pyrene is that the fluorescent probes are
reporting on behavior of Ah in different membrane environ-
ments as a function of probe location and probe lifetime.
Most of the studies on Ah and membranes have examined
fluidity. However, there are additional membrane structural
properties that could be altered by Ah. Membrane fluidity is a
general term used to describe the movement of lipids in
membranes. Actually, fluidity consists of different compo-
nents including, for example, rate of probe motion, a dynamic
component, and extent of probe motion, a static component
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[48–50]. Time-resolved fluorescence of DPH can be used to
differentiate between limiting anisotropy (order) and rota-
tional relaxation time (rate). Ah is an amphipathic molecule
and another amphipathic molecule, ethanol, has been shown
to reduce limiting anisotropy but had no effect on rotational
relaxation time [51]. Effects of Ah on limiting anisotropy and
rotational relaxation time have not been reported. Lifetimes
of fluorescence probes were discussed in the preceding
paragraph and it should be mentioned that a fluorescent probe
can have multiple lifetimes and would be indicative of
different membrane environments [47]. Lifetime distribution
may be altered by Ah and effects dependent on Ah protein
structure.
Another structural property of membranes that may play
an important role in protein function is curvature of the
bilayer [52,53]. Both positive and negative curvature strain
may facilitate function of proteins depending on the lipid
composition of the membrane and the specific protein [52].
The action of certain peptides is thought to involve changes
in curvature strain [53]. It has been suggested that Ah may
induce negative curvature strain in membranes [17] and this
conclusion was based on results showing Ah promotion of
dehydration of lipid interfacial groups and some reduction
in ordering of acyl groups.
Ah has several different effects on membrane structure.
Ah-induced changes in neuronal functions (e.g., ion flux,
calcium homeostasis, enzyme activity and signal transduc-
tion) may be initially precipitated by the cumulative effects of
disruptions in different membrane structural properties.
4. Cholesterol and AD
There is growing interest in the potential contribution of
cholesterol in the pathogenesis of AD. Actually, this contri-
bution can be considered from the perspective of two major
questions. The first question is whether changes in cholesterol
homeostasis are a causative factor in AD. The second ques-
tion asks if cholesterol homeostasis is a target of AD partic-
ularly with respect to Ah. Ostensibly, these questions may
appear to be an exercise in ‘‘circular reasoning’’. However, it
is our view that the answer to both questions is indeed yes.
Data of clinical studies on cholesterol and AD indicate that
patients on statins have a lower risk of developing AD as
compared with individuals not taking statins [12,13]. Lova-
statin and pravastatin were associated with a reduced risk of
AD, but treatment with simvastatin was not associated with a
lower risk. Several interesting conclusions and questions can
be drawn from these data. Obviously, statins as a drug class
do not equally act on expression of AD. Statin-induced
inhibition of HMG-CoA reductase and reduction of choles-
terol do not explain the lower AD risk reported. All three
drugs inhibit HMG-CoA reductase and reduce plasma cho-
lesterol. Effects of pravastatin and lovastatin imply both a
peripheral and potential CNS effect of the two drugs, respec-
tively. Pravastatin is hydrophilic, does not readily partition
into cell membranes, does not cross the blood–brain barrier
and is thought to be taken up into cells by an active transport
mechanism [54,55]. Both lovastatin and simvastatin are
hydrophobic and can intercalate into membranes and prob-
ably do cross the blood–brain barrier. Lovastatin has been
detected in the CSF of normal human subjects whereas
pravastatin was not detected [55].
Another important distinction among the three statins is
the active form of the drug that inhibits HMG-CoA reductase.
Lovastatin and simvastatin are administered as lactones and
then metabolized to lovastatin acid and simvastatin acid, each
having an open hydroxyl moiety, and it is this acid metabolite
that acts on HMG-CoA reductase whereas pravastatin acts
directly on the enzyme [54]. There is evidence suggesting that
lovastatin and simvastatin in the lactone form cross the
blood–brain barrier by simple diffusion and the acid form
of the two statins crosses the blood–brain barrier by means of
a transport mechanism for monocarboxylic acid [56]. An
overriding conclusion is that there is very little information on
the pharmacokinetics and pharmacodynamics of statins in
brain. This is a topic that is sorely in need of attention. It is not
known if it is the lactone or acid form of lovastatin that may
reduce the risk of AD. Moreover, what is the mechanism
whereby a statin that does not cross the blood–brain barrier
appears to be associated with reducing the risk of AD? It
could be argued that plasma cholesterol levels and brain
cholesterol levels are in equilibrium and lowering plasma
cholesterol also lowers brain cholesterol. However, plasma
cholesterol and brain cholesterol are not in equilibrium. A
very pointed example of differences in plasma cholesterol
and brain cholesterol is comparisons between wild-type mice
and apoE-deficient mice. Plasma cholesterol was approxi-
mately sevenfold higher in apoE-deficient mice as compared
with wild-type mice [57]. There were no differences in brain
cholesterol amounts between the two groups. Similar results
have been reported for SPM of wild-type mice and apoE-
deficient mice [58]. Effects of statins on AD expression may
be independent of their action on cholesterol levels. It has
been shown for example that statins induce upregulation of
COX-2 and stimulation of apoptosis, and reduce expression
of endothelin-1 [59–61]. Recently, it was reported that
lovastatin and compactin inhibited vasoconstriction and
inflammation induced by soluble Ah1–40 in rat aortae [62].
Lovastatin also reduced Ah1–40 induction of prostaglandin
E2 and F2a in rat aortae. There is considerable interest in the
role of inflammation in AD and that topic has been reviewed
in detail elsewhere [2,63]. Risk of AD may be lowered by
statins as a result of a reduction in proinflammatory products
occurring both peripherally and in brain.
If bulk brain cholesterol amount was a factor in AD, then it
is reasonable to predict that cholesterol content in brain of AD
patients would differ as compared to brain cholesterol of non-
AD individuals. However, data on cholesterol content of
brain tissue of Alzheimer’s patients have been equivocal.
There was a small but significant increase in frontal cortex
gray matter of AD patients (2.65F 0.14 mg/g wet tissue
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weight) with the apoE4 genotype compared with apoE4
control subjects (2.04F 0.18) [64]. Conversely, it was
reported that cholesterol content was lower in the temporal
gyrus of autopsied brains of AD patients in contrast to control
subjects [65]. The cholesterol-to-phospholipid ratio of the
temporal gyrus was reduced by 30% in the AD brains and no
differences were observed in the cholesterol-to-phospholipid
ratio in cerebellum of the two groups. The reduction in the
cholesterol-to-phospholipid ratio in the temporal gyrus was
attributed to cholesterol because the phospholipid-to-protein
ratio was similar in brains of both groups. Cholesterol content
did not differ in hippocampal tissue of AD patients as
compared with control subjects [38]. HMG-CoA reductase
mRNA levels in brain were indistinguishable between AD
samples and control samples and it was suggested that
cholesterol synthesis may be unaffected by AD [66]. While
levels of HMG-CoA reductase mRNAwere similar between
the two groups, there could be posttranslational changes in
the enzyme that could alter its activity and in turn modify
cholesterol synthesis. Activity of HMG-CoA reductase has
been shown to be regulated by processes such as phosphor-
ylation and cAMP that could be altered in AD patients. In
addition, a metabolite of brain cholesterol, 24S-hydroxycho-
lesterol, was found to be elevated in CSF of AD patients
compared with control subjects and it was concluded that
there was an increased turnover of cholesterol in AD patients
[67]. This oxysterol is thought to be important in regulation of
brain cholesterol homeostasis [68]. Changes in levels of 24S-
hydroxycholesterol would imply changes in cholesterol turn-
over but it is not clear how such changes relate to the amount
of cholesterol in brain. A humbling fact is that the biosyn-
thesis of cholesterol is most complicated, requiring over 30
different enzymes and several cofactors [69]. An understand-
ing of cholesterol biosynthesis in brain and its role in AD is
only beginning.
Whether the total amount of cholesterol in brains of AD
patients is either increased or decreased has not been estab-
lished. Numerous differences (e.g., other pathology, tissue
preparation and brain region) in the studies could account for
the lack of consistent effects. More importantly, cholesterol
amounts may differ depending on brain region and some
brain regions more affected by AD than other brain regions.
To that end, the amount of SPM cholesterol has a distribution
with the hippocampus>cerebral cortex>cerebellum [44].
Effects of Ah1–40 on SPM fluidity were positively correlated
with cholesterol amount. Cholesterol domains in contrast to
changes in the total amount of cholesterol may be targets of
AD [70,71] and this issue will be discussed later in this
review.
5. Cholesterol and expression of AB and APP
Changes in the amount of cholesterolmodify expression of
APP and Ah. Rabbits administered with dietary cholesterol
showed an accumulation of Ah in brain [10]. Administration
of diets high in cholesterol increased Ah accumulation in
brain tissue of double-mutant transgenic mice (PSAPP) over-
expressingAPP (Tg2567) and presenilin 1 (PS1) as compared
with transgenic controls [72]. There was a small but signifi-
cant increase (16.68 mg/g) in cholesterol in brain tissue of
mice fed the high-cholesterol diets compared with controls
(14.76 mg/g). In contrast to the studies reporting that choles-
terol diets increased Ah expression, it was found that a high-
cholesterol diet reduced Ah expression in brain of APP-gene-
targeted mice [73]. Total brain cholesterol was unaffected by
the cholesterol diet and a small but significant increase in
cholesterol was observed in the frontal cortex of mice on the
cholesterol diet. The most striking finding was the large
increase in apoE in serum and frontal cortex of the mice on
cholesterol diets. Differences in the genetic background of the
mouse animal models employed may account for the con-
trasting results as previously suggested [72]. Levels of Ah1–
42 and Ah1–40 were reduced by simvastatin in brain and CSF
of guinea pigs [74]. Interestingly, brain cholesterol content
was unaffected by simvastatin treatment in guinea pigs in
contrast to an 83% reduction in plasma cholesterol. There was
a significant reduction in brain lathosterol, which is one of the
last two precursors to cholesterol [75], and it was concluded
that simvastatin treatment reduced de novo brain cholesterol
synthesis. If brain cholesterol synthesis was reduced, any
effects would be negligible at best because total brain choles-
terol was unaffected and the half life of cholesterol in rat brain
has been calculated to be approximately 6 months [76]. The
absence of effects of simvastatin on brain cholesterol amount
differs from a study showing that lovastatin significantly
reduced brain cholesterol in C57BL/6J mice [57]. Further-
more, as discussed earlier, human studies indicated that
lovastatin reduced AD risk and simvastatin had no effect
[12,13].
Regardless of the effects of alterations in cholesterol on
Ah expression, changes in brain cholesterol are modest.
Administration of cholesterol in diets may have a substantial
effect on cholesterol domains as compared with the total
amount of cholesterol. It also is possible that redistribution of
cholesterol occurs within the cell involving different intra-
cellular organelles or perhaps transport between cell types
such as astrocytes and neurons. Another issue is the extent to
which cholesterol administered in the diet can cross the
blood–brain barrier. A low-density lipoprotein receptor has
been identified in endothelium of brain capillaries [77] and it
has been suggested that cholesterol and other lipids could be
delivered to the brain by the transcytosis of LDL across the
blood–brain barrier [78]. However, data on LDLR-deficient
mice would argue against such a mechanism. It was reported
that the total amount of SPM cholesterol was similar for
LDLR-deficient mice as compared with control mice [58]. If
the LDLR is involved in transport of cholesterol across the
blood–brain barrier, then it would be expected that brain
cholesterol content would be lower in LDLR-deficient mice.
On the other hand, cholesterol content in other membrane
types, cell types or brain regions may be differentially
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affected in comparison with SPM. What is needed is a
detailed study of subcellular membrane fractions of different
brain regions of animals administered with dietary choles-
terol. In addition, such an approach would be very useful with
respect to animal models of AD. A question that has not been
fully answered is whether there are differences in either total
cholesterol or specific cholesterol domains in animal models
of AD. If cholesterol actually plays a role in expression of
APP and Ah, then a reasonable prediction is that brain
cholesterol content or cholesterol domains would differ
between animal models of AD andwild-type controls without
dietary manipulation. However, a recent report showed that
there were no differences in cholesterol levels, cholesterol
precursors and metabolites in brain homogenates of different
age groups (3, 6, 9, 12 and 18months of age) of wild-type and
APP23 transgenic mice[79]. A caveat regarding those data is
that a brain homogenate preparation is heterogeneous in brain
region and cell type. Moreover, differences between wild-
type and APP mice in cholesterol distribution and cholesterol
domains could occur in the absence of differences in the total
amount of cholesterol.
Studies in cell culture have shown that modification of
cholesterol amounts altered APP and Ah expression. Choles-
terol added to APP 751 stably transfected human embryonic
kidney cells reduced the production of soluble APP, which is
a nonamyloidogenic derivative, but increased production of
APP holoprotein [80]. Cholesterol reduction in human
embryonic kidney cells and astroglioma cells stimulated
production of soluble APP [81]. Depletion of cholesterol by
lovastatin and methyl-h-cyclodextrin inhibited the produc-
tion of Ah formation in hippocampal neurons that had been
infected with Semliki Forest virus encoding human APP695
[82]. In the same study it was observed that a portion of APP
was located in fraction that has been described as lipid rafts.
Other studies have found that APP, as well as Ah, and
presenilin-1 were located in cholesterol-enriched membrane
domains [25,27,83,84]. Caveolin-3 that is associated with a
type ofmembrane domain identified as caveolae was found to
be upregulated in astrocytes nearby senile plaques in brain
tissue of AD patients and brain tissue ofmice that overexpress
the human APP with the Swedish mutation [85]. In addition
to the importance of cholesterol domains in Ah synthesis,
inhibition of intracellular transport of cholesterol by
U18666A reduced cleavage of Ah from APP in neuronal
cells [86].
A question that has not been addressed in the cell culture
studies of APP, Ah and cholesterol reduction is what other
effects does reduction of large amounts of cholesterol have on
normal cell structure and function. It is certainly well estab-
lished that cholesterol in mammalian cells is required for
membrane structure and activity of various proteins [87–89].
For example, a relatively small reduction (5% to 10%) of
cholesterol in SPM resulted in a 40–50% decrease in
Ca2 + +Mg2 +-ATPase activity [90]. Membrane interdigita-
tion was significantly reduced and membrane fluidity was
significantly increased in that study. Cholesterol reduction in
synaptosomes and SPM produced a significant impairment in
sodium-dependent GABA uptake, a reduction of GABA-
binding sites [91]. On the other hand, cholesterol enrichment
of neurons altered GABA receptor function, particularly in
the presence of neurosteroids [92–94].
Reducing cholesterol levels appear to decrease the pro-
motion of APP and Ah. However, there are data indicating
that cholesterol may act to attenuate the effects of Ah.
Cholesterol protected PC12 cells from Ah toxicity in vitro
and inhibited effects of Ah on cellular calcium signaling
[35,95]. This observation was supported by recent findings
of enhanced cholesterol levels and reduced disordering
effects of Ah peptides in SPM of aged mice [39].
6. Ah modifies cholesterol dynamics
Cholesterol modifies APP and Ah expression. On the
other hand, Ah impacts on cholesterol homeostasis. Ah1–40
and Ah1–28 inhibited cholesterol esterification in plasma
[96]. Both free and esterified cholesterol synthesis were
reduced by Ah1–40 in HepG2 cells [97]. Cholesterol ester-
ification was inhibited by Ah1–40 in rat neurons of primary
cell culture [98]. Cholesterol transport into and out of cells
was altered by Ah. Ah stimulated the uptake of apoE–
cholesterol complexes into rat astrocytes [99]. Ah1 – 40
induced the removal of cholesterol from rat hippocampal
neurons to 2-hydroxypropyl-h-cyclodextran [98]. A recent
study reported that oligomeric Ah1–40 stimulated the release
of cholesterol, PC and GM1-ganglioside from rat cultured
neurons and astrocytes [100]. Fresh Ah and fibrillar Ah had
little if any effect on lipid release. Effects of Ah on lipid efflux
may result from direct interaction of Ah with lipids and
modification of Golgi function. Ah1–40 preincubated for
different periods of time up to 24 h binds lipids with binding
of cholesterol>stearic acid>PC [101]. Lipid binding occurred
when Ah polymers were present as compared with mono-
mers and dimmers. The Golgi complex is involved in
regulation of cholesterol efflux [102,103] and Ah modifies
cholesterol content in the Golgi complex of astrocytes and
neurons from primary cell culture [104]. Soluble Ah1–42
significantly increased cholesterol in the Golgi complex in
astrocytes and neurons. Aggregated Ah1–42 had quite the
opposite effect with a significant reduction in cholesterol
content occurring in the Golgi complex of both cell types.
Reduction of cholesterol in the Golgi complex by aggregated
Ahmay be in response to the removal of cholesterol from the
cell plasma membrane induced by Ah.
7. Transbilayer distribution of cholesterol and AD: a
hypothesis
Cholesterol is associated with AD but evidence suggesting
that changes in the bulk amount of brain cholesterol are a
contributing factor in the pathogenesis of AD has not been
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forthcoming. We propose instead (Fig. 1) that alterations in
the transbilayer distribution of cholesterol in SPM in contrast
to changes in the total amount of cholesterol acts to promote
synthesis of Ah and could also restrict efflux of the peptide
from membranes. The two greatest risk factors for late-onset
AD are increasing age and inheritance of the apolipoprotein
E4 allele. SPM cholesterol asymmetry is altered in aged mice
and SPM of human apoE4 knockin mice [105,106]. The SPM
Fig. 1. Model of transbilayer distribution of cholesterol in the SPM exofacial (Exo.) and cytofacial (Cyto.) leaflets of C57BL/6J mice (3–4 and 24–25 months
of age) and human ApoE3 and ApoE4 knock-in mice (2 months of age). Panel A shows the transbilayer cholesterol distribution in SPM of mice 3–4 and 24–
25 months of age. Panel B shows transbilayer cholesterol distribution in SPM of human ApoE3 and ApoE4 knock-in mice. Percent distribution of cholesterol is
shown for each leaflet. Ah synthesis and movement into and out of membranes may be affected by an increase in cholesterol of the exofacial leaflet. Both
accumulation of cholesterol and Ah could promote peptide polymerization, alter lipid rafts, and disrupt integral membrane proteins. C, cholesterol; P,
phospholipids; red structures, amyloid beta-protein. Modified from Ref. [71].
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exofacial leaflet contains approximately 15% of total SPM
cholesterol and the cytofacial leaflet 85% [58,105–107].
There was a doubling of cholesterol in the SPM exofacial
leaflet of aged mice as compared with younger mice [105].
Total SPM cholesterol did not differ with age. Recently, it was
reported that mice expressing human apoE4 had substantially
more cholesterol in the exofacial leaflet in contrast to the
exofacial leaflet of mice expressing human apoE3 and wild-
type mice [106]. Total SPM cholesterol did not differ among
the three groups. As discussed earlier in this paper, an
increase in cholesterol amount enhances expression of APP
and Ah. In addition, APP, Ah and presenilin-1 have been
identified in cholesterol enriched membrane domains
[24,25,27,83,84]. It has been suggested that these cholesterol
domains may reside in the membrane exofacial leaflet [108].
Cholesterol catalyzed the fibrillogenesis of soluble Ah
[109,110]. Taken together, the structure and lipid composi-
tion of the exofacial leaflet may play an important role in Ah
dynamics. Certainly there is much more work that needs to be
done in understanding the potential role of cholesterol asym-
metry of the exofacial and cytofacial leaflets and Ah dynam-
ics. It would be worthwhile to determine if differences in the
transbilayer distribution of cholesterol occur in brain tissue
from humans with the apoE3 and apoE4 alleles. In addition,
mechanisms regulating cholesterol asymmetry are not under-
stood. Several potential mechanisms have been proposed
(sterol carrier protein-2, fatty acid binding proteins, apoE,
LDLR) whose dysfunction may precede the development of
AD [70,71,88].
8. Conclusions
Ah is thought to be a primary factor in the pathogenesis of
AD. This protein has a physico-chemical relationship with
membranes and cholesterol. Ah-induced changes in mem-
brane structure can certainly contribute to alterations in cell
function. The effects of Ah on membrane structure are
heterogeneous, acting dissimilarly in different membrane
locations. Cholesterol is a major component of plasma
membranes and cholesterol may be both a promoter and a
target of Ah. Certain statins that lower cholesterol levels
would appear to reduce the risk of AD. However, whether
changes in the total amount of cholesterol, peripherally or in
brain, are responsible for the reduced risk of AD is not
known. Pharmacokinetics and pharmacodynamics of statins
in brain is an area of research that is sorely in need of
attention. Administration of statins in cell culture is problem-
atic for two important reasons. Both lovastatin and simvas-
tatin have to be metabolized before these drugs can inhibit
HMG-CoA reductase. In the absence of brain levels of these
drugs, it is not known what form of the drug or how much of
the drug is in the brain. Another concern is that typically
cholesterol is reduced by over 50% in cell culture studies.
While APP and Ah expressions are reduced many other
proteins as well as the membrane environment will be altered.
Finally, a hypothesis is proposed that does not rely on
changes in the total amount of cholesterol but instead predicts
that redistribution of cholesterol from the cytofacial leaflet to
the exofacial leaflet acts to promote APP and Ah expressions
and disrupts membrane structure, including fluidity and lipid
rafts and various cell functions such as ion flux and choles-
terol transport. Increasing age and inheritance of the apoE4
allele are the two greatest risk factors for late-onset AD and
both conditions result in the doubling of cholesterol in the
exofacial leaflet, which in combination could be additive.
Obviously there are many more questions than there are
answers concerning the role of cholesterol in the pathogenesis
of AD. An important benefit of the widening interest in
cholesterol and AD is that it has substantially increased an
understanding of the biochemistry of brain cholesterol.
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